Mymetics’ first malaria vaccine candidate is using the influenza virosome as the carrier and adjuvant with the incorporation of at least three antigens that target the two forms of the parasite and is thereby one of the few vaccine developed with this approach
The second malaria vaccine candidate is a transmission blocking vaccine which also uses the Mymetics virosome technology by incorporating a transmission blocking antigen from the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the NIAID.
The transmission-blocking vaccine candidate seek to interrupt the life cycle of the parasite by inducing antibodies that prevent the parasite from maturing in the mosquito after it takes a blood meal from a vaccinated person.
Nemo (diveblu3.com/nemo) is the world’s only diving system with an electronic regulator, which would be modified to serve as a respiration detector sensing the breathing of a patient. Minor software modifications can convert Nemo into a machine that behaves like a ventilator with minimal added cost since Nemo already includes a breathing air pump, respiration sensor, and spare microcontroller capacity. If selected, the team projects that BLU3 Ventilator can be produced at a rate of approximately 2,500 units per week within a 2-week startup period and at a fraction of the cost of currently-available ventilators. BLU3 Ventilator can run continuously with access to wall-power or it can be powered with commonly available 12 volt DC batteries.